How Much Does Rezdiffra (Resmetirom) Cost in Ohio?

Ohio Retail Pricing for Rezdiffra in 2026

Rezdiffra's wholesale acquisition cost (WAC) from Madrigal Pharmaceuticals sits at $3,500 per month nationally, and Ohio retail pharmacies reflect this same figure for cash-pay patients. That number places resmetirom among the higher-cost specialty oral medications, though it remains less expensive than many injectable biologics used in liver disease.

Why the Price Is Consistent Across Ohio

Unlike drugs with wide geographic price variation, resmetirom is distributed through specialty pharmacy channels that enforce uniform pricing. Whether you fill at a CVS Specialty location in Columbus, a Kroger Specialty Pharmacy in Cincinnati, or an independent specialty pharmacy in Cleveland, the sticker price will hover around the same $3,500 mark.

How Resmetirom Pricing Compares Nationally

Ohio's pricing tracks with the national average. Rezdiffra launched in March 2024 following its FDA accelerated approval as the first drug specifically indicated for MASH with moderate to advanced hepatic fibrosis (stages F2, F3). The annual cost of approximately $42,000 per patient reflects Madrigal's positioning against the long-term costs of liver transplantation, which exceed $800,000 in the first year alone according to UNOS transplant cost data.

The clinical justification for this pricing rests largely on the MAESTRO-NASH trial (N=966), published in the New England Journal of Medicine in 2024, which demonstrated that resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared with 9.7% for placebo [1]. A secondary endpoint showed fibrosis improvement by at least one stage in 25.9% of the resmetirom 100 mg group versus 14.2% for placebo [1].

Ohio Medicaid and Rezdiffra: What's Covered

Ohio Medicaid does not currently reimburse Rezdiffra for its FDA-approved MASH indication. Coverage is restricted to patients with type 2 diabetes, where the drug may be prescribed off-label through a separate clinical pathway.

Why Ohio Medicaid Excludes MASH Coverage

State Medicaid formularies operate under budget constraints that often delay inclusion of newly approved specialty drugs. Because resmetirom received accelerated (not full) FDA approval, Ohio's Medicaid Pharmacy and Therapeutics Committee has not yet added it to the preferred drug list for MASH. This mirrors the approach taken by roughly 60% of state Medicaid programs nationwide as of early 2026.

Options for Ohio Medicaid Enrollees

If you are on Ohio Medicaid and have been diagnosed with MASH with fibrosis, your prescriber can submit an exception request. Approval rates for these exceptions remain low, but documentation of advanced fibrosis (F3) and failed lifestyle interventions strengthens the case. Patients denied through Medicaid may also qualify for Madrigal's patient assistance program, which provides free drug to uninsured or underinsured individuals earning below 400% of the federal poverty level.

Dr. Zobair Younossi, chairman of the Global NASH Council and a hepatologist at Inova Health System, has stated: "Access to resmetirom for patients with progressive MASH fibrosis is a clinical urgency, not an elective choice. These patients face cirrhosis and liver failure without pharmacological intervention" [2].

Commercial Insurance Coverage in Ohio

Most major commercial health plans operating in Ohio cover Rezdiffra, though all require prior authorization and step therapy documentation. The plans with confirmed formulary inclusion as of 2026 include Anthem Blue Cross Blue Shield of Ohio, Medical Mutual, Molina Healthcare, UnitedHealthcare, and SummaCare.

Prior Authorization Requirements

Ohio insurers typically require three elements before approving Rezdiffra: (1) imaging or biopsy evidence of MASH with fibrosis stage F2 or F3, (2) documentation of at least 6 months of lifestyle modification attempts, and (3) prescribing by or in consultation with a hepatologist or gastroenterologist. Some plans also require a FibroScan (vibration-controlled transient elastography) score above 8.0 kPa.

Typical Copay Tiers

On most Ohio commercial plans, Rezdiffra falls on specialty tier 4 or tier 5, producing copays between $150 and $500 per month before any manufacturer assistance. Plans with coinsurance structures rather than flat copays may charge 20 to 33% of the drug cost, which would translate to $700, $1,155 monthly without the savings card.

Self-Funded Employer Plans

Ohio has a large self-funded employer market, particularly among manufacturing and healthcare system employers. Self-funded plans set their own formulary rules and may be more flexible than fully insured products. If your employer self-funds its health plan, ask your HR benefits team whether Rezdiffra has been added to the formulary, as these decisions happen independently of state insurance regulations.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers a copay assistance program that can reduce out-of-pocket costs to $0 per month for commercially insured patients. The card covers up to $13,000 in annual copay or coinsurance costs.

Eligibility Criteria

To qualify, you must have commercial (private) insurance that covers Rezdiffra. Patients on Medicare, Medicaid, TRICARE, or other government-funded programs are not eligible for the savings card. There is no income requirement for commercially insured patients.

How to Enroll in Ohio

Enrollment happens through Madrigal's patient support hub, RezdiffraConnect. Your prescriber's office can initiate enrollment at the time of prescribing, or you can call the hub directly. Processing takes 3 to 5 business days. Once approved, the savings card is applied automatically at the specialty pharmacy each fill cycle.

Annual Benefit Reset

The $13,000 annual cap resets each calendar year. For a patient with a $350 monthly copay, this cap covers the full 12-month supply. Patients with coinsurance-based plans that produce monthly costs above $1,083 may exhaust the benefit before year-end and should plan accordingly.

Compounded Resmetirom in Ohio

Ohio permits compounding of resmetirom through licensed 503A pharmacies. A 503A pharmacy compounds patient-specific prescriptions based on a valid individual prescription from a licensed prescriber.

Legal Status in Ohio

The Ohio State Board of Pharmacy regulates 503A compounding facilities under Ohio Revised Code Chapter 4729. As long as the pharmacy holds a valid Ohio Terminal Distributor of Dangerous Drugs license and follows USP compounding standards, producing compounded resmetirom is legal. However, 503B outsourcing facilities (which compound without patient-specific prescriptions) have not widely listed resmetirom in their catalogs.

Cost Considerations

Compounded resmetirom, where available through a 503A pharmacy, may be offered at significantly reduced cost compared to brand Rezdiffra. Pricing varies by pharmacy and is not standardized. Patients should be aware that compounded versions are not FDA-approved, are not AB-rated as therapeutically equivalent to Rezdiffra, and may differ in bioavailability. The FDA's guidance on compounding recommends discussing these differences with your prescriber.

Finding a 503A Pharmacy in Ohio

Ohio has licensed compounding pharmacies in most major metro areas, including Columbus, Cleveland, Cincinnati, Dayton, and Akron. Your prescriber or the Ohio State Board of Pharmacy's online license verification tool can help identify facilities that compound resmetirom specifically.

Telehealth Access to Rezdiffra in Ohio

Ohio allows telehealth prescribing of Rezdiffra. No in-person visit is required to initiate or maintain a resmetirom prescription, provided the prescriber establishes a valid patient-prescriber relationship through a synchronous audio-video encounter.

How Telehealth Prescribing Works

Ohio's telehealth parity law (Ohio Revised Code § 3902.30) requires insurers to cover telehealth visits at the same rate as in-person visits. A hepatologist or gastroenterologist licensed in Ohio can evaluate your imaging results, lab work, and clinical history via video, then electronically prescribe Rezdiffra to a specialty pharmacy.

Practical Considerations for Ohio Patients

Telehealth is especially valuable for patients in rural Ohio counties without nearby hepatology practices. The state has 88 counties, but hepatologists are concentrated in Cuyahoga (Cleveland), Franklin (Columbus), and Hamilton (Cincinnati) counties. Telehealth removes the geographic barrier to specialist access.

A 2023 analysis published in Hepatology Communications found that telehealth-based hepatology care produced equivalent medication adherence rates compared with in-person care over 12 months, with a 23% reduction in missed appointments [3].

Strategies to Lower Your Rezdiffra Cost in Ohio

Reducing what you actually pay for resmetirom requires combining multiple pathways. No single approach works for every patient, but several options exist beyond the sticker price.

Step 1: Confirm Your Insurance Formulary Status

Call the member services number on the back of your insurance card and ask whether resmetirom (brand name Rezdiffra) is on the formulary. If it is, ask which tier and what the prior authorization criteria are. Get this in writing.

Step 2: Apply for the Madrigal Savings Card Simultaneously

Do not wait for insurance approval to start the savings card application. Your prescriber's office can submit both the prior authorization and the RezdiffraConnect enrollment on the same day. This parallel processing can shave 1 to 2 weeks off your time to first fill.

Step 3: Appeal Denials Promptly

Ohio insurance regulations (Ohio Administrative Code 3901-1-01) give you 180 days to file an internal appeal after a denial. If the internal appeal fails, you can request an external review through the Ohio Department of Insurance. The external review is binding on the insurer.

Step 4: Explore the Madrigal Patient Assistance Program

Uninsured patients or those denied by both commercial insurance and Medicaid may qualify for free Rezdiffra through Madrigal's patient assistance program. Income thresholds apply. Contact RezdiffraConnect for application details.

According to the AASLD 2023 Practice Guidance on NAFLD, pharmacotherapy should be considered for all patients with biopsy-confirmed NASH and fibrosis stage F2 or higher, regardless of the presence of cirrhosis [4]. This guideline language can strengthen insurance appeals.

What Ohio Patients Should Know About Dosing and Costs

Rezdiffra is dosed based on body weight at initiation. Patients with a BMI <33 start at 80 mg once daily; patients with BMI ≥33 start at 100 mg once daily. Both strengths carry the same $3,500 monthly list price.

Monitoring Costs to Factor In

Beyond the drug itself, resmetirom requires periodic liver function monitoring. The FDA label recommends hepatic panel testing at baseline, monthly for the first 3 months, then every 3 months thereafter [5]. Each hepatic panel costs $15, $50 with insurance, but this adds up over a year of treatment.

Duration of Therapy

Rezdiffra is not a short-course medication. The MAESTRO-NASH trial evaluated outcomes at 52 weeks, and continued benefit requires ongoing treatment [1]. Budget planning should account for at least 12 months of therapy, with reassessment of fibrosis status (typically via FibroScan or MR elastography) guiding continuation decisions.

Dr. Stephen Harrison, medical director of Pinnacle Clinical Research, noted in a 2024 Journal of Hepatology commentary: "Resmetirom represents the first mechanism-targeted therapy for MASH. Treatment duration should be guided by fibrosis regression on serial imaging, not arbitrary time limits" [6].

Ohio-Specific Resources for MASH Patients

Ohio has several institutional resources for patients navigating MASH treatment costs. The Cleveland Clinic's Digestive Disease & Surgery Institute, Ohio State University Wexner Medical Center's hepatology division, and University of Cincinnati's Liver Center all maintain financial counseling services that help patients maximize insurance benefits and access manufacturer programs.

Ohio Department of Insurance

The Ohio Department of Insurance (ODI) operates a consumer hotline (1-800-686-1526) that can help you understand your rights when an insurer denies coverage for Rezdiffra. ODI also publishes an annual report on specialty drug prior authorization denial rates by insurer, which can inform your choice of plan during open enrollment.

Ohio Pharmacy Discount Programs

Some Ohio-based pharmacy benefit managers (PBMs) negotiate supplemental discounts on specialty drugs. If your plan uses OptumRx, Express Scripts, or CVS Caremark, ask whether any supplemental discount applies to Rezdiffra specifically. These discounts are plan-specific and not publicly listed.

The annual cost burden for untreated MASH with advanced fibrosis averages $7,804 per patient in direct medical costs according to a 2022 analysis in Hepatology, rising to $23,661 annually once cirrhosis develops [7]. For patients with F2, F3 fibrosis, the $42,000 annual cost of resmetirom must be weighed against the cost trajectory of disease progression.